Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 9/20 | 0.53 |
| ▸ | CDK2 | P24941 | 9/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.53 |
| ▸ | BRD4 | O60885 | 2/20 | 0.49 |
| ▸ | CDK4 | P11802 | 5/20 | 0.49 |
| ▸ | CCND3 | P30281 | 5/20 | 0.49 |
| ▸ | GSK3B | P49841 | 5/20 | 0.49 |
| ▸ | PIM1 | P11309 | 4/20 | 0.49 |
| ▸ | MTOR | P42345 | 3/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.47 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | CCNK | O75909 | 1/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3496128 | 0.91 | CHEK1 (0.48) | CCNA2CDK2CCNA1BRD4 | |
| SCHEMBL1741098 | 0.91 | BRD4 (0.46) | CCNA2CDK2CCNA1BRD4CDK4 | |
| SCHEMBL3495081 | 0.90 | CDK4 (0.53) | CCNA2CDK2CCNA1BRD4CDK4 | |
| SCHEMBL3495623 | 0.89 | BRD4 (0.59) | CCNA2CDK2CCNA1BRD4CDK4 | |
| SCHEMBL1741267 | 0.89 | CDK2 (0.53) | CCNA2CDK2CCNA1BRD4CDK4 | |
| SCHEMBL1743517 | 0.89 | PAK1 (0.49) | BRD4SLC2A1PKMYT1 | |
| SCHEMBL3496765 | 0.88 | EGFR (0.55) | CCNA2CDK2CCNA1BRD4CDK4 | |
| SCHEMBL3497842 | 0.85 | KDR (0.50) | CDK2BRD4CDK4SLC2A1PKMYT1 | |
| SCHEMBL3497197 | 0.84 | CCNA2 (0.56) | CCNA2CDK2CCNA1BRD4CDK4 | |
| SCHEMBL3494581 | 0.84 | BRD4 (0.53) | CCNA2CDK2CCNA1BRD4CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | claimed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | claimed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | claimed |
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | CCNA2 1000/4885CDK2 129/4885CCNA1 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.